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Dialysate aluminium concentration and renal bone disease
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Dialysate aluminium concentration and renal bone disease. We studied
40 patients maintained on regular hemodialysis. using radiology and
quantitative bone histology to assess the relationship between renal
bone disease and exposure to aluminium. Fractures were significantly
more common in patients exposed to high dialysate aluminium concen-
trations. The histologic indices of osteomalacia were significantly
related to the prevailing dialysate aluminium concentration, in such a
way that higher aluminium levels were associated with more osteomala-
cia. Patients who had been exposed to higher concentrations of
aluminium also tended to have a lower plasma phosphate concentra-
tion, and associated hypercalemia was seen in 6 patients with osteoma-
lacia. These findings suggest that aluminium is a toxic agent associated
with a mineralizing defect in the bone of renal failure patients. This may
explain the incomplete response of some patients with renal osteomala-
cia to administration of I ,25-dihydroxy vitamin D.
Concentrations de l'aluminium dans le dialysat et ostéodystrophie.
Nous étudiâmes 40 malades en hémodialyse chronique du point de vue
radiologique et par l'histologie osseuse quantitative afin d'évaluer Ia
relation entre l'osteodystrophie rénale et l'exposition a !'aluminium.
Les fractures ont été significativement plus nombreuses chez les
malades exposés a des concentrations élevées d'aluminium dans le
dialysat. Les signes histologiques d'ostéomalacie Ont été significative-
ment lies a Ia concentration d'aluminium dans le dialysat de telle sorte
que les niveaux les plus élevés d'aluminium étaient associés avec
l'ostéomalacie Ia plus intense. Les malades qui ont été exposés aux
concentrations les plus élevées d'aluminium avaient tendance a avoir
les concentrations les plus basses de phosphate plasmatique, et une
hypercalcémie associée a été observée chez 6 malades atteints d'ostéo-
malacie. Ces constatations suggèrent que l'aluminium est un agent
toxique associé avec un deficit de minéralisation de l'os chez les
malades en insuffisance rénale. Cela peut expliquer La réponse incom-
plete de quelques malades atteints d'ostéomalacie rénale a l'administra-
tion de l,25-dihydroxy vitarnine D.
In patients developing dialysis dementia, now generally con-
sidered to be due to aluminium intoxication [1], a higher
incidence of bone disease has been observed [2, 3]. Several
authors have suggested that bone disease may be an additional
manifestation of aluminium intoxication [4, 6].
A major component of renal bone disease both clinically and
radiologically is osteomalacia, a defect in calcification, which is
revealed in the severest cases by pseudofractures. In milder
forms of the disease and in the absence of typical radiologic
features, the diagnosis is dependent on bone histology. There is
general agreement that in osteomalacia there is an increase in
the extent of osteoid tissue as assessed by surface area, volume,
and seam thickness, in conjunction with a reduction in calcifica-
tion fronts. But there is no general agreement which of these
variables should be used to define osteomalacia, especially in a
complex metabolic state such as renal failure.
The osteomalacia of renal failure is resistant to "physiologic"
doses of vitamin D, and administration of the renal metabolite
(1,25-dihydroxy vitamin D) does not produce improvement in
all patients [7]. Patients resistant to 1,25-dihydroxy vitamin D
therapy usually have lower plasma phosphate and higher calci-
um concentrations than do other renal patients, and it would
appear that other factors are operating to produce or maintain
osteomalacia in these patients.
We have therefore looked retrospectively at patients exposed
to high concentrations of aluminium in domestic water, to
assess the relationships between aluminium exposure, the pres-
ence of fracture, and the biochemical and histologic variables
commonly used for diagnosing osteomalacia.
Methods
Forty patients (10 females and 30 males; ages, 18 to 53 yr),
maintained on hemodialysis for periods of 0.5 to 8.25 years were
studied retrospectively. Eight were maintained on hospital dialy-
sis, and the remainder were dialyzed at separate home installa-
tions. Home dialysis was undertaken with dialysate prepared from
softened domestic water (Permutit-Boby, domestic type 17L).
The patients on hospital hemodialysis were exposed to a dialy sate
prepared from deionized water in which aluminium content was
negligible. Dialysis was undertaken using a Kiil-type dialyzer with
a Meltic multipoint board of 1.0 or 1.5 m2. The dialysate calcium
was adjusted to 1.5 mmoles/liter.
At the time of study, no patient was taking any form of
vitamin D supplement, and most patients had never received
such therapy. Aludrox was routinely prescribed to all hemodial-
ysis patients when plasma phosphate control was inadequate by
dialysis alone. The dose varied from 20 to 80 ml daily, depend-
ing on the predialysis plasma phosphate concentration. As this
study was retrospective, no precise data on the total intake of
oral aludrox was available. In addition, patient compliance is
usually poor with these agents, and so producing meaningful
data to assess the effect of oral aludrox, although desirable, was
not possible.
The diet was essentially unrestricted, and the calcium intake
in most patients is well above the recommended daily intake of
500 mg/day. Only one patient had previously undergone para-
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Table 1. Comparison of two groups of patients maintained on chronic hemodialysis
Variable
Group I: Evidence
of fracture
(N = 15)
Group 2: No evidence
of fracture
(N = 25) U test P
Time on hemodialysis, yr 3.3 0.4 2.4 0.4 253 NS
Mean water aluminium concentration, mg/liter 0.17 0.03 0.09 0.08 277 <0.01
Total exposive to aluminium, mg/liter/yr 0.45 0.08 0.29 0.08 267 <0.03
Bone volume, % 20.3 2.4 23.2 1.8 143 NS
Osteoid volume, % 4.8 1.0 2.9 0.6 250 NS
Trabecular osteoid volume, % 22.5 3.5 11.9 2.0 287 <0.005
Osteoid index 40.1 4.0 31.2 4.2 265 <0.03
Osteoid surfaces, % 53.2 5.5 42.9 5.3 237 NS
Calcification fronts, % 46.9 5.5 60.6 4.4 122 NS
Resorptive surfaces, % 17.1 2.0 19.0 1.8 172 NS
Plasma calcium, mmoles/liter 2.64 0.07 2.5 0.05 218 NS
Plasma phosphate, mmoles/liter 2.08 0.14 2.20 0.13 156 NS
Plasma alkaline phosphatase, K.A. units/liter 15.6 3.4 14.7 3.6 252 NS
Plasma 25-OH vitamin D, p.g/liter 31.8 3.3 28.9 4.2 209 NS
thyroidectomy (3 years before), although a further five patients
have subsequentially needed such surgery.
The mean aluminium concentration of the domestic water
supplied to all dialysis installations was obtained by analyzing
the water at monthly intervals from the first month of hemodial-
ysis. These data were available from records kept by the local
Water Authority. Aluminium was measured spectrophotometri-
cally with catechol violet complex [8]. This method relates well
to other analytic methods [4] and is capable of detecting
aluminium concentrations in water below 50 p.g/liter. From
these monthly estimations, we obtained a mean value of the
water aluminium concentration. The length of exposure was
taken as the time on hemodialysis, and these two figures
multiplied together gave us an estimate of total exposure to
aluminium.
All patients had an iliac crest bone biopsy and a full radiologic
skeletal survey on two occasions at 6-month intervals. From
these x-ray films, we determined the presence or absence of
fractures, At the time of bone biopsy, blood samples were taken
for measurement of calcium, phosphate, and alkaline phospha-
tase by standard methods, and 25-hydroxy vitamin D by the
method of Morris et al [9]. The samples of bone were assessed
by quantitative histology for percentage bone volume, percent-
age osteoid volume, percentage of surfaces covered in osteoid,
percentage of surfaces showing resorption, and percentage of
forming surfaces with calcification fronts [101. Normal ranges
for our laboratory are bone volume 15 to 30% of total tissue,
osteoid volume <1% of total tissue, surfaces with osteoid
(forming surfaces) 2 to 24%, surfaces with resorption (resorbing
surfaces) <12%, and calcification fronts >60%.
From these data, we determined the trabecular osteoid
volume, that is, the percentage of bone tissue occupied by
osteoid (normal range, <4%), and the osteoid index
=
trabecular osteoid volume
% osteoid surfaces x 100
(normal range, 14.5 to 23.5) [11]. These indices may assist in
defining osteomalacia in some patients, but a preferred dis-
criminant by our group is to use the method of Bordier [121.
Osteomalacia is considered to be present if the percentage of
surfaces covered with osteoid is greater than 24% and if the
percentage of osteoid surfaces with a calcification front is less
than 60%. Assessment of mineralization rate by double tetracy-
cline labeling is useful but not essential; the biopsies were done
before we had introduced this technique.
All data were assessed for normal distribution by obtaining
the ratio of standard deviation to mean, and assessing the
distribution by tests for Kurtosis and Skewness. From this
information it was found that most of the data was non-normally
distributed, and even logarithmic transformation did not correct
the distribution. Therefore nonparametric tests were used to
analyze the data; the Mann-Whitney U test was used to
compare populations, and Spearman's coefficient (rho) for the
significance of correlation. In addition, Chi squared test was
used to compare nonnumerical data, and multiple regression
analysis was applied to the data.
Results
Of the 40 patients studied, 15 had radiologic evidence of
fracture on a skeletal survey performed just prior to bone
biopsy or developed fractures during the following 6 months.
The fractures were often asymptomatic and occurred in the ribs
(all 15 patients), pelvis (2 patients), and vertebral bodies (I
patient). The group with radiologic evidence of fractures was
compared with the larger group, with no evidence of fracture
seen. The results are shown in Table I. Variables significantly
different in the two groups were the mean water aluminium
concentration (P < 0.01) and the total exposure to aluminium (P
<0.03). In addition, the percent trabecular osteoid volume (P <
0.005) and the osteoid index (P < 0.03) were also significantly
different; bone volumes were almost the same and well within
the normal range. The other indices for osteomalacia were not
significantly different but they were always more abnormal in
the fracturing group. These data indicate that fractures are
associated with high water aluminium concentration and his-
tologic osteomalacia.
Patients with osteomalacia as defined by the Bordier method
were compared with the patients without osteomalacia (Table
2). Again there was a significant difference between the groups
in the mean water aluminium concentration (P < 0.003) and the
total exposure to aluminium (P < 0.04). There was also a
significant difference in many of the histologic parameters: the
percent osteoid volume, percent trabecular osteoid volume,
percent osteoid surfaces, and percent calcification fronts were
all significantly worse in the osteomalacic group. The osteoid
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Table 2. Comparison of two groups of patients maintained on chronic hemodialysis
Variable
Group 1:
With osteomalacia
(N = 19)
Group 2:
Without osteomalacia
(N = 21) U test P
Time on hemodialysis, yr 2.71 0.31 2.83 0.52 213 NS
Mean water aluminium concentration, mg/liter 0.17 0.03 0.07 0.02 309 <0.003
Total exposive to aluminium, mg/liter/yr 0.45 0.09 0.27 0.07 277 <0.04
Bone volume, % 25.8 2.2 18.8 1.5 292 <0.01
Osteoid volume, % 6.0 0.9 1.5 0.2 363 <0.0001
Trabecular osteoid volume, % 24.1 3.1 8.4 0.8 344 <0.0001
Osteoid index 38.0 3.7 31.5 4.9 268 NS
Osteoid surfaces, % 60.7 4.7 34.2 4.8 329 <0.0005
Calcification fronts, % 38.2 3.2 71.1 3.6 30.5 <0.0001
Resorptive surfaces, % 15.4 1.7 20.9 2.0 136 NS
Plasma calcium, mmoles/liter 2.59 0.05 2.52 0.06 218 NS
Plasma phosphate, mmoles/liter 1.95 0.10 2.35 0.14 120 <0.03
Plasma alkaline phosphatase, K.A. units/liter 17.4 4.9 12.8 2.0 217 NS
Plasma 25-OH vitamin D, p.g/liter 31.0 3.2 29.2 4.6 208 NS
Table 3. Relationship between mean water aluminuin concentration
and other parameters
X (mean water aluminum conc.)
Y rho P
%Bone volume —0.06 NS
% Osteoid volume 0.40 <0.01
% Trabecular osteoid volume 0.46 <0.003
% Osteoid surfaces 0.38 <0.015
% Calcification fronts —0.52 <0.001
Osteoid Index 0.22 NS
% Resorptive surfaces —0.27 NS
Plasma phosphate —0.49 <0.002
Plasma calcium 0.19 NS
Plasma alkaline phosphatase 0.38 <0.015
Plasma 25-hydroxy vitamin D 0.39 <0.014
index, however, did not show a significant difference between
the groups, although the values were markedly elevated in both
populations and more abnormal in the osteomalacic patients.
There was no difference in the 25-hydroxy vitamin D or alkaline
phosphatase activities, The plasma phosphate concentration
was significantly lower (P < 0.03) in the osteomalacic group.
Further analysis was done by dividing the patients into those
exposed to higher water aluminium concentration (arbitrarily
defined as those with levels over 0.15 mg/liter) and those
exposed to lower levels. The only significant differences found
among the parameters was a significantly lower percent calcifi-
cation fronts (P < 0.001) in the group exposed to high alumin-
ium concentrations. The plasma phosphate concentration was
also significantly lower (P < 0.02) in this group exposed to high
aluminium.
Exposure to aluminium via domestic water was assessed in
several ways. Tables 1 and 2 show that mean water aluminium
concentration seems to have the strongest association with
fracture and osteomalacia. Table 3 shows the relationship
between mean water aluminium concentration and other param-
eters, which correlates with all indicators of osteomalacia
except the osteoid index. The most significant correlation is
with the calcification fronts (P < 0.001). Mean water aluminium
concentration also correlates negatively with plasma phosphate
concentration (P < 0.002) and positively with alkaline phospha-
tase concentration (P < 0.015).
Chi-squared (x2) tests were performed to assess further the
relationship between fracture, osteomalacia as defined by Bor-
dier's method, and exposure to "high" water aluminium con-
centration (> 0.15 mg/liter). Osteomalacia was significantly
related to the presence of fracture (x2 = 4.9 P < 0.03), but
fracture was not significantly related to "high" water alumin-
ium concentration (x2 = 2.4). Osteomalacia was also signifi-
cantly related to "high" water aluminium concentration (x2=
13.03, P < 0.001) (see Fig. I).
Concentrations of 25-hydroxy vitamin D and phosphate in
plasma were found not to correlate significantly with any of the
indicators for osteomalacia. In addition, no patient had phos-
phate concentrations in the predialysis hypophosphatemic
range, that is, below 1.33 mmoles/liter [291. Plasma calcium
concentrations were found not to correlate significantly with
any of the other parameters, but 9 individual patients were
hypercalcemic, and of these, 6 had associated osteomalacia as
defined by Bordier's method.
Multiple regression analysis was applied to the data to try and
help clarify the various relationships. It only helped for phos-
phate, aluminium, and the incidence of osteomalacia. In almost
all cases, aluminium was a much stronger determinant for
osteomalacia than was phosphate. For example, with calcifica-
tion fronts alone, aluminium was a determinant in 23.7% of the
abnormalities, and when phosphate was also taken into account
this value improved only slightly to 24.6%. With Bordier's
osteomalacic group, the corresponding figures were 19.2% for
aluminium alone and 21.6% when aluminium and phosphate
were considered together.
Discussion
These results show that fractures in patients on hemodialysis
were associated with osteomalacia rather than osteopenia. The
definition of osteomalacia in histologic terms is contentious,
and it remains debatable which criteria most accurately distin-
guish between osteomalacic biopsies and nonosteomalacic find-
ings from biopsy samples. As fractures are due to osteomalacia
in these patients, the presence or absence of fracture may help
clarify the histologic criterion most helpful for separating the
groups. The results show a significantly higher osteoid index, a
higher percentage of trabecular osteoid volume, and a higher
incidence of osteomalacia (as defined by Bordier's method) in
the fracturing group. The parameter showing the most signifi-
cant difference, and by inference the best discriminant, is the
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Fig. 1. Prevalence of osteomalacia and its relationship to mean
dialysate aluminium concentration
percentage of trabecular osteoid volume. There is no significant
advantage between osteoid index and the Bordier method in
terms of their ability to separate the fracturing from the
nonfracturing groups, and both methods are useful in defining
severe osteomalacia of renal bone disease. The major difference
between the osteoid index and Bordier's method is a quantita-
tive difference. In this series, 27 patients are considered to have
osteomalacia with an osteoid index over 23.5%, whereas by
Bordier's method only 19 patients have osteomalacia, that is,
calcification fronts below 60% and osteoid surfaces above 24%.
This greater sensitivity" of the osteoid index method may not
necessarily be an advantage as more borderline cases with
smaller degrees of abnormality are defined as abnormal, and
causal relationships may be obscured. This may explain why in
our data the osteoid index is not significantly correlated to the
mean water aluminium concentration, whereas there is a strong
relationship between aluminium and osteomalacia as defined by
Bordier's method.
Fractures due to osteomalacia are seen in patients with higher
water aluminium concentrations and greater exposure to alu-
minium, suggesting a possible causal relationship. The mean
water aluminium concentration also correlates with all osteo-
malacic criteria except osteoid index: The most significant
correlation is with calcification fronts, probably suggesting a
direct inhibitory effect on the calcification mechanisms. The
association between dialysate aluminium and renal bone dis-
ease has been suggested by several groups [2—61. Clinically,
they have found more severe bone disease and, radiologically,
an increased incidence of fracture among dementing patients.
An epidemiologic survey of 18 dialysis centers in the United
Kingdom showed a significant correlation between osteomala-
cic dialysis bone disease and the aluminium content of domestic
water [4]. More direct evidence for a causal relationship be-
tween aluminium and osteomalacia has been produced by Ellis,
McCarthy, and Herrington [13] and Cournot-Witmer et al [14],
Rats with normal renal function given daily i.p. injections of
aluminium chloride developed high bone levels of aluminium
and histologic osteomalacia [131. They also found high alumin-
ium concentrations in the bones of dialysis patients, but were
unable in the human study to find any significant relationship
between bone aluminium content and bone mineralization.
Another group [141 have shown in a limited number of patients a
relationship between aluminium content of bone and percentage
of osteoid volume, suggesting that aluminium may interfere
with bone mineralization in man.
The effect of aluminium on bone has been little studied even
though it is known that aluminium can accumulate in the bone
of patients with renal failure to levels ten times above normal
[13, 151. The cause of aluminium accumulation is probably
multifactorial. The patients all have severe renal disease and
impaired normal excretory mechanisms [16]. It is also known
that in renal failure intestinal absorption of aluminium occurs
[17] and that administration of oral aluminium hydroxide in-
creases tissue concentrations of aluminium. The contribution
from oral Aludrox® administration to the overall exposure to
aluminium could not be assessed in our patients because of the
retrospective nature of the study. Although a contribution
undoubtedly occurs from this source, the most important
source of aluminium is probably the water supply during
dialysis [18]. There is considerable variation in the aluminium
content of domestic water [4], studies from our own area
confirm this finding (unpublished observations). The transfer of
aluminium from domestic water to plasma during hemodialysis
has been confirmed [19], and has been found to be true even at
low concentrations of dialysate aluminium. The transfer ap-
pears to depend on the dialysate concentration, but once
absorbed the aluminium is protein bound, so there is no free
diffusion from the plasma.
Aluminium is known to accumulate in the bone [13, 15],
blood [20], and brain tissue [21, 22] of patients with renal
failure. The biologic effects of these high levels of aluminium on
the relevant tissues have been little studied. There is evidence
that aluminium salts can inhibit mitosis in vitro [23], can inhibit
the enzyme hexokinase [161, and can induce neurofibrillary
spheroids and tangles in central and peripheral neurones [24,
25]. In vivo studies in rabbits have also shown that aluminium
administration is associated with neurofibrillary degeneration
[261. In man high concentrations of aluminium have been found
in patients with neurofibrillary degeneration of Alzheimer's
disease [27]. There is evidence that aluminium may also inter-
fere with the orderly deposition of bone [28], in that aluminium
at concentrations of 1 p. or less can inhibit, by forming
insoluble phosphates, precipitation of calcium apatite. Through
such a mechanism, aluminium could cause local phosphate
depletion and so interfere with normal mineralization. It would
be a situation in some ways analogous to that seen in hypophos-
phatemic osteomalacia. There is therefore some evidence
showing that aluminium is toxic, in a variety of ways, to
biologic tissues. The experimental evidence that aluminium is
directly toxic to bone is poor, but the results of the present
study suggest that exposure to high aluminium is associated
with significantly more osteomalacia and radiologic evidence of
fracture. The association, however, may be fortuitous, and
aluminium may act as a marker for some other toxic environ-
mental factor.
Osteomalacia as defined by Bordier's method is associated
with a significantly lower plasma phosphate. As hypophospha-
temia can lead to osteomalacia, this may explain some of the
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osteomalacia seen in these patients. But no patient was truly
hypophosphatemic, the lowest predialysis phosphate concen-
tration being 1.34 mmoles/liter, which is considered adequate to
prevent postdialysis hypophosphatemia [29]. The plasma phos-
phate concentration is not related significantly to any of the
other histologic criteria for osteomalacia, including the osteoid
index. A strong correlation exists, however, between plasma
phosphate and mean water aluminium concentration. The evo-
lution of osteomalacia suggests that low plasma phosphate
concentration may result from aluminium intoxication rather
than act as a causal factor. This view is supported by the results
of multiple regression showing that the plasma phosphate
concentration, when studied with aluminium concentration,
makes only a minor contribution to the overall incidence of
osteomalacia. The osteomalacia was not related to different
concentrations of 25-hydroxy vitamin D, these being normal in
most patients.
Plasma calcium was not significantly different in any of the
various groups, but when the data was examined individually,
there were six patients with both osteomalacia and hypercalce-
mia. They were not the patients with the lowest phosphates.
The reason for this association remain unclear, although it
probably reflects the failure of mineralization.
Within the osteomalacic group, there are a few patients with
osteomalacia and no exposure to high water aluminium concen-
trations (see Fig. 1). This suggests that some renal osteomalacia
is due to factors other than aluminium, that is. I ,25-dihydroxy
vitamin D deficiency. These findings support the concepts of
Pierides et al [7], who have found that some osteomalacias
respond to 1,25-dihydroxy vitamin D but that others are quite
resistant despite high plasma levels of the metabolite and
demonstrable intestinal effect. Certainly, if a toxic agent can be
shown to inhibit bone mineralization in renal failure, this would
explain in part the complexity of renal bone disease and the
failure of some patients with renal osteomalacia to respond to
1,25-dihydroxy vitamin D.
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